Pharmaceutical News

RSS

Two synergistic therapies allow solid tumors to act as their own cancer-fighting vaccine

Researchers in the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute eradicated solid tumors in laboratory mice using a novel combination of two targeted agents. These two synergistic therapies stimulate an immune response, ultimately allowing solid tumors to act as their own cancer-fighting vaccine.

13 Mar 2014

Perrigo launches methazolamide tablets

Perrigo Company today announced that it has launched, through a distribution and supply agreement, methazolamide tablets, the generic equivalent to Neptazane tablets. This product is a component of the contingent rights Perrigo received in connection with its acquisition of a portfolio of ophthalmic products from Fera Pharmaceuticals, LLC and its affiliates in June of last year.

12 Mar 2014

EPFL sets up foundation to release antibiotic for tuberculosis

Even though tuberculosis kills more than 1.5 million people every year, the market is not cost-effective for pharmaceutical companies. So EPFL is setting up a foundation to release an antibiotic developed in its own laboratories under EU funding.

12 Mar 2014

CPhI to conduct the 4th NEXTGEN China 2014 Conference from March 27 to 28

In March 2012, the 1st Nextgen China was held successfully in Shanghai. FDA, USP, national institutes for Food and Drug Control and leading pharmaceutical companies from home and abroad were invited to give presentations.

12 Mar 2014

Experimental drugs offer hope for people with hepatitis C

Patrizia Cazzaniga had heard the horror stories about early treatments for hepatitis C - multiple daily pills and weekly shots for up to a year, side effects that could be debilitating, and a cure rate of only about 40 percent.

11 Mar 2014

MedVantx MedStart Connect program increases patient initiation of new prescriptions

New research presented today at the World Congress Summit to Improve Adherence and Enhance Patient Engagement by researchers from the University of Pittsburgh School of Pharmacy, finds that a unique generic medication sampling program, the MedVantx MedStart™ Connect program, implemented in the primary care physicians' office, led to significantly increased patient initiation of new prescriptions (primary adherence) as well as continued use of the medications (secondary adherence), and could possibly lead to savings for health plans.

11 Mar 2014

"Doctor shopping" results in increased drug use among postoperative orthopaedic trauma patients

"Doctor shopping," the growing practice of obtaining narcotic prescriptions from multiple providers, has led to measurable increases in drug use among postoperative orthopaedic trauma patients, according to a new study presented today at the 2014 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS).

11 Mar 2014

AAOHN, ACOEM collaborate to study workplace health and safety issues linked with use of marijuana

The American Association of Occupational Health Nurses (AAOHN) and the American College of Occupational and Environmental Medicine (ACOEM) have announced they will collaborate to study workplace health and safety issues associated with worker impairment from the use of marijuana and other drugs.

11 Mar 2014

Statins combined with conventional blood clot prevention therapies, reduce VTE risk by 48%

Statins have long been known to lower cholesterol and, more recently, to decrease the risk of deep vein thrombosis (blood clots) in healthy, non-surgical patients.

11 Mar 2014

A pill may provide hope to relapsed leukemia and lymphoma patients

A pill that suppresses a key regulator of cancer growth may provide hope to relapsed leukemia and lymphoma patients running out of treatment options for their aggressive, treatment-resistant disease, according to three reports published online today in Blood, the journal of the American Society of Hematology.

10 Mar 2014

Regado receives Fast Track designation from FDA for REG1

Regado Biosciences, Inc., a biopharmaceutical company focused on the development of actively controllable therapeutics, today announced that the United States Food and Drug Administration has designated REG1 for anticoagulant therapy to be used in patients with coronary artery disease during percutaneous coronary interventions (PCI) as a Fast Track development program.

10 Mar 2014

FDA accepts Lundbeck's carbamazepine NDA for review

Lundbeck LLC today announced that the U.S. Food and Drug Administration has accepted for review a New Drug Application (NDA) for its investigational therapy intravenous carbamazepine, an intravenous formulation of the anti-epileptic drug (AED) carbamazepine. An action letter is anticipated before the end of 2014. Carbella is the proposed U.S. trade name for intravenous carbamazepine.

10 Mar 2014

ABC Varro E. Tyler Commercial Investment in Phytomedicinal Research Award presented to Wakunaga

The American Botanical Council has presented its 2013 Varro E. Tyler Commercial Investment in Phytomedicinal Research Award to Wakunaga Pharmaceutical Company, Ltd., of Osaka, Japan. Since its founding in 1955, the company has been committed to rigorous scientific and clinical research of its products, including its top-selling, clinically researched odorless Aged Garlic Extract¨.

10 Mar 2014

BerGenBio receives grant to study novel therapeutics for inhibiting epithelial-mesenchymal transition

BerGenBio AS, an oncology biopharmaceutical company, is pleased to announce the award of a NOK 13 million grant from the Research Council of Norway's User-driven Research based Innovation programme (BIA) to help fund research into novel therapeutics for inhibiting tumor epithelial-mesenchymal transition (EMT), a key driver of metastasis (cancer spread) and a mechanism of drug-resistance.

10 Mar 2014

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma, Inc. today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

10 Mar 2014

Fibrotech successfully completes Phase Ia trial of anti-fibrotic compound FT011

Fibrotech, an Australian biopharmaceutical company developing a new class of drugs to prevent a massive health burden associated with fibrosis, today announced that its lead anti-fibrotic compound FT011 has successfully completed a Phase Ia trial in healthy volunteers demonstrating safety and tolerability up to doses of 1000mg.

10 Mar 2014

Erlotinib has promising potential to improve treatment for cervical cancer

A new clinical study has found that erlotinib, a targeted antitumor agent, has promising potential to improve treatment for cervical cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the results indicate that larger trials are warranted to determine whether the drug should become part of standard therapy for women with the disease.

10 Mar 2014

Dr. Daniel D. Von Hoff named one of ASCO's 50 Oncology Luminaries

In association with its 50th anniversary, the American Society of Clinical Oncology has named Dr. Daniel D. Von Hoff one of ASCO's 50 Oncology Luminaries, celebrating 50 doctors who over the past half-century have significantly advanced cancer care.

9 Mar 2014

FDA-approved anti-psychotic drugs possess tumor-killing activity against glioblastoma

Researchers at the University of California, San Diego School of Medicine have discovered that FDA-approved anti-psychotic drugs possess tumor-killing activity against the most aggressive form of primary brain cancer, glioblastoma. The finding was published in this week's online edition of Oncotarget.

8 Mar 2014

Teva launches generic Xeloda Tablets in the U.S.

Teva Pharmaceutical Industries Ltd. announces the launch of the generic equivalent to Xeloda (Capecitabine) Tablets, 150 MG and 500 MG, in the United States. Xeloda is marketed by Genentech in the United States.

8 Mar 2014

Pharmaceutical News

Two synergistic therapies allow solid tumors to act as their own cancer-fighting vaccine

Perrigo launches methazolamide tablets

EPFL sets up foundation to release antibiotic for tuberculosis

CPhI to conduct the 4th NEXTGEN China 2014 Conference from March 27 to 28

Experimental drugs offer hope for people with hepatitis C

MedVantx MedStart Connect program increases patient initiation of new prescriptions

"Doctor shopping" results in increased drug use among postoperative orthopaedic trauma patients

AAOHN, ACOEM collaborate to study workplace health and safety issues linked with use of marijuana

Statins combined with conventional blood clot prevention therapies, reduce VTE risk by 48%

A pill may provide hope to relapsed leukemia and lymphoma patients

Regado receives Fast Track designation from FDA for REG1

FDA accepts Lundbeck's carbamazepine NDA for review

ABC Varro E. Tyler Commercial Investment in Phytomedicinal Research Award presented to Wakunaga

BerGenBio receives grant to study novel therapeutics for inhibiting epithelial-mesenchymal transition

Antares Pharma announces launch of OTREXUP to Dermatologists

Fibrotech successfully completes Phase Ia trial of anti-fibrotic compound FT011

Erlotinib has promising potential to improve treatment for cervical cancer

Dr. Daniel D. Von Hoff named one of ASCO's 50 Oncology Luminaries

FDA-approved anti-psychotic drugs possess tumor-killing activity against glioblastoma

Teva launches generic Xeloda Tablets in the U.S.

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News